Gerstein HC, et al. – In this multicenter, randomized, double-blind, placebo-controlled trial involving 9,901 individuals with type 2 diabetes with and without previous cardiovascular disease and a wide range of glycemic control, researchers investigated the effect of dulaglutide on major adverse cardiovascular events when added to the existing anti-hyperglycemic regimens. Nearly half of all participants in the dulaglutide group experienced a gastrointestinal adherent event during follow-up vs just over one-third of participants in the placebo group. Overall, however, the investigators concluded that dulaglutide could be considered for glycemic control regulation in middle-aged and older people with type 2 diabetes with either previous cardiovascular disease or cardiovascular risk factors.